368 related articles for article (PubMed ID: 28910565)
1. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
4. Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg.
Chen Q; Li W; Wang P; Shao H; Ding Y; Wang W; Cen D; Cai Y; Xue X; Zhang L; Zhu G
Protein Pept Lett; 2017; 24(10):947-954. PubMed ID: 28641561
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D; Altorki NK; Stockert E; Williamson B; Jungbluth AA; Ritter E; Santiago D; Ferrara CA; Matsuo M; Selvakumar A; Dupont B; Chen YT; Hoffman EW; Ritter G; Old LJ; Gnjatic S
J Immunol; 2004 Mar; 172(5):3289-96. PubMed ID: 14978137
[TBL] [Abstract][Full Text] [Related]
7. Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.
Pollack KE; Meneveau MO; Melssen MM; Lynch KT; Koeppel AF; Young SJ; Turner S; Kumar P; Sol-Church K; Mauldin IS; Slingluff CL
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32350119
[TBL] [Abstract][Full Text] [Related]
8. Effects of poly(I:C) and MF59 co-adjuvants on immunogenicity and efficacy of survivin polypeptide immunogen against melanoma.
Jiang X; Guan S; Qiao Y; Li X; Xu Y; Yang L; Kuai Z; Zhang H; Shi Y; Kong W; Shan Y; Zhang H
J Cell Physiol; 2018 Jun; 233(6):4926-4934. PubMed ID: 29206298
[TBL] [Abstract][Full Text] [Related]
9. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
10. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
11. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.
Pampena MB; Cartar HC; Cueto GR; Levy EM; Blanco PA; Barrio MM; Mordoh J
Front Immunol; 2018; 9():2531. PubMed ID: 30450100
[TBL] [Abstract][Full Text] [Related]
13. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization.
Hafner C; Wagner S; Jasinska J; Allwardt D; Scheiner O; Wolff K; Pehamberger H; Wiedermann U; Breiteneder H
J Invest Dermatol; 2005 Jan; 124(1):125-31. PubMed ID: 15654965
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.
Reed CM; Cresce ND; Mauldin IS; Slingluff CL; Olson WC
Clin Cancer Res; 2015 Sep; 21(17):3879-87. PubMed ID: 25967144
[TBL] [Abstract][Full Text] [Related]
15. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
16. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
17. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
[TBL] [Abstract][Full Text] [Related]
18. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.
Speiser DE; Liénard D; Pittet MJ; Batard P; Rimoldi D; Guillaume P; Cerottini JC; Romero P
Eur J Immunol; 2002 Mar; 32(3):731-41. PubMed ID: 11870617
[TBL] [Abstract][Full Text] [Related]
19. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Filipazzi P; Pilla L; Mariani L; Patuzzo R; Castelli C; Camisaschi C; Maurichi A; Cova A; Rigamonti G; Giardino F; Di Florio A; Asioli M; Frati P; Sovena G; Squarcina P; Maio M; Danielli R; Chiarion-Sileni V; Villa A; Lombardo C; Tragni G; Santinami M; Parmiani G; Rivoltini L
Clin Cancer Res; 2012 Dec; 18(23):6485-96. PubMed ID: 23032742
[TBL] [Abstract][Full Text] [Related]
20. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
